AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
| Revenue (TTM) | $60.44B |
| Gross Profit (TTM) | $49.26B |
| EBITDA | $20.03B |
| Operating Margin | 27.90% |
| Return on Equity | 23.50% |
| Return on Assets | 8.49% |
| Revenue/Share (TTM) | $39.00 |
| Book Value | $30.56 |
| Price-to-Book | 6.23 |
| Price-to-Sales (TTM) | 4.88 |
| EV/Revenue | 5.21 |
| EV/EBITDA | 15.63 |
| Quarterly Earnings Growth (YoY) | 5.30% |
| Quarterly Revenue Growth (YoY) | 12.50% |
| Shares Outstanding | $1.55B |
| Float | $1.54B |
| % Insiders | 0.05% |
| % Institutions | 68.25% |
Volatility is currently expanding
AZN shares tumble after Wainua missed the primary endpoint in a late-stage ATTR-CM study, raising questions about its expansion into a larger market.
The damage to AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) from Wainua's trial failure is less about the numbers than about a dent to management's credibility, according to Jefferies. The shares fell 9% and topped the FTSE 100 fallers' list, a move the broker expects to exceed the drug's actual contribution to valuation.
Stock futures are slightly higher this morning as investors monitor developments in the Middle East; PepsiCo's results narrowly beat Wall Street estimates as strength in international markets offset sluggish sales in North America; Korean memory chip maker SK Hynix is reportedly seeing heavy demand for its upcoming U.S. stock listing; AstraZeneca shares are sinking after a disappointing heart drug trial; and Levi Strauss shares are falling after the denim apparel maker issued weak guidance. Here's what you need to know today.
The UK's FTSE 100 declined on Thursday as investors assessed renewed tensions in the Middle East, while pharmaceutical heavyweight AstraZeneca weighed heavily on the benchmark after reporting disappointing results from a late-stage clinical trial. The blue-chip FTSE 100 index fell 0.6% to 10,417.63 points by 10:45 GMT.
AstraZeneca and California-based biotech Ionis Pharmaceuticals announce a late-stage trial failure for their gene silencing drug, Wainua.
AstraZeneca shares slumped nearly 10% on Thursday after the drugmaker said its nerve disease treatment Wainua failed to achieve the primary objective in a late-stage clinical trial for a serious heart condition, dealing a setback to one of its most closely watched pipeline assets. The stock fell about 9.5% in London trading, making it the biggest loser on the FTSE 100 index.
AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares fell 9.55% in early trading, wiping £19 billion from the company's valuation, after its Wainua drug failed a closely watched Phase III trial in a form of heart disease. The drop propelled the stock to the top of the FTSE 100 losers' list.
AstraZeneca stock dives 9% after heart drug trial misses target
The drug trial for a rare type of heart disease showed the treatment was generally well tolerated but it did not work than a placebo.
AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis , failed to meet the main goal of reducing cardiovascular deaths and recurring heart problems in a late-stage trial.
